Metformin improves the angiogenic potential of human CD34+ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction

Abstract

BackgroundCardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with diabetes mellitus (DM). To identify the most effective treatment for CVD, it is paramount to understand the mechanism behind cardioprotective therapies. Although metformin has been shown to reduce CVD in Type-2 DM clinical trials, the underlying mechanism remains unexplored. CD34+ cell-based therapies offer a new treatment approach to CVD. The aim of this study was to investigate the effect of metformin on the angiogenic properties of CD34+ cells under conditions mimicking acute myocardial infarction in diabetes.MethodsCD34+ cells were cultured in 5.5 or 16.5 mmol/L glucose ± 0.01 mmol/L metformin and then additionally ± 4 % hypoxia. The paracrine function of CD34+ cell-derived conditioned medium was assessed by measuring pro-inflammatory cytokines, vascular endothelial growth factor A (VEGFA), and using an in vitro tube formation assay for angiogenesis. Also, mRNA of CD34+ cells was assayed by microarray and genes of interest were validated by qRT-PCR.ResultsMetformin increased in vitro angiogenesis under hyperglycemia–hypoxia and augmented the expression of VEGFA. It also reduced the angiogenic-inhibitors, chemokine (C–X–C motif) ligand 10 (CXCL10) and tissue inhibitor of metalloproteinase 1 (TIMP1) mRNAs, which were upregulated under hyperglycemia–hypoxia. In addition metformin, increased expression of STEAP family member 4 (STEAP4) under euglycemia, indicating an anti-inflammatory effect.ConclusionsMetformin has a dual effect by simultaneously increasing VEGFA and reducing CXCL10 and TIMP1 in CD34+ cells in a model of the diabetic state combined with hypoxia. Therefore, these angiogenic inhibitors are promising therapeutic targets for CVD in diabetic patients. Moreover, our data are commensurate with a vascular protective effect of metformin and add to the understanding of underlying mechanisms.Electronic supplementary materialThe online version of this article (doi:10.1186/s12933-016-0344-2) contains supplementary material, which is available to authorized users.

Does Metformin Protect Against Diabetic Retinopathy in Albino Rats? An Immunohistochemical Study

“…This finding may be explained by MT induced vitamin B12 deficiency and subsequent hyperhomocysteinemia which could contribute to the development of retinal neovascularization through stimulation of VEGF expression by retinal cells [58]. This result was in line with Bakhashab, et al (2016) [22] who ensured that metformin induced endothelial cells angiogenesis by augmenting the expression of VEGF and reducing angiogenic inhibitors in CD34 + cells under hyperglycemia and hypoxia in vitro. On the contrary, Zhang, et al (2017) [19] stated that MT significantly alleviated the severity of DR through attenuating the retinal neovascularization by suppressing VEGF protein.…”

MicroRNA-29b-3p Promotes Human Retinal Microvascular Endothelial Cell Apoptosis via Blocking SIRT1 in Diabetic Retinopathy

“…and advanced glycation, thus promoting inflammation (Miyata and de Strihou, 2010;Chiu and Taylor, 2011). The experimental model of hyperglycemia and hypoxia conditions is widely used in the research of diabetic complications (Bakhashab et al, 2014(Bakhashab et al, , 2016. In this study, we constructed an in vitro hyperglycemia and hypoxia model with HRMEC to investigate the diabetic vascular damage mechanism.…”

Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study

“…In this experiment, metformin improved angiogenesis through increased angiogenic signal. It not only increased VEGF-A levels but also downregulated angiogenic inhibitors; CXCL-10 and TIMP-1 [52]. …”